Frost Radar™: Life Sciences Real-World Evidence Solutions, 2025

Healthcare Frost Radar™: Life Sciences Real-World Evidence Solutions, 2025

A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines

INDUSTRY
Healthcare

RELEASE DATE
23-May-2025
REGION
Global
DELIVERABLE TYPE
Frost Radar

RESEARCH CODE
MHB8-01-00-00-00
SKU
HC_2025_33515
Yes
SHARE

$4,950.00

Special Price $4,455.00 save 10 %

In stock
SKU
HC_2025_33515

Frost Radar™: Life Sciences Real-World Evidence Solutions, 2025
Published on: 23-May-2025 | SKU: HC_2025_33515

Need more details?

$4,950.00

$4,455.00 save 10 %

Need more details?

The evolving IT landscape has played a transformative role in the field of life sciences, enabling a reliance on real-world evidence (RWE) solutions. With growing competition and the demand for precision in decision-making, pharmaceutical companies, healthcare providers, and technology organizations have realized the need for real-world data (RWD) to boost research while optimizing clinical trials and improving patient outcomes.

The platforms and enabling technologies help pharma/biotech companies harness regulatory-grade RWE across the product lifecycle, including early-stage research, clinical development, launch planning, value-based contracting, long-term patient monitoring, and patient activation.

The life sciences RWE solutions industry is fragmented, with about 120 vendors operating in this space across areas including data aggregation, integration, interoperability, and predictive analytics to provide pharmaceutical companies with high-quality insights.

Frost & Sullivan screened and analyzed more than 45 RWE solution vendors and short-listed the leading 16 companies based on a detailed analysis of their corporate growth potential and ability to drive visionary innovation in this industry. This Frost Radar™ benchmarks companies primarily in data integration, management, analytics, and insights with a strong play in the data collection segment. Solutions in other segments and enabling technologies had a positive impact on their ratings.

When benchmarking vendors, Frost & Sullivan evaluated their portfolios across key criteria, such as data integration, data quality, advanced analytics, scalability, real-time access, cloud support, collaboration, regulatory expertise, patient-centric approaches, innovation, agility, and cost-effectiveness to ensure that life sciences companies partner with the best vendor for their evolving and customized needs.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar™. The publication presents competitive profiles of each company on the Frost Radar™ considering their strengths and the opportunities that best fit those strengths.

Author: Unmesh Lal

Aetion

Clarify Health

COTA Healthcare

Flatiron Health

Inovalon

IQVIA

Komodo Health

Merative

OM1

Optum Life Sciences

Oracle Health

Pharmaceutical Product Development

Picnic Health

TriNetX

Verana Health

Veradigm

Best Practices

Growth Opportunities

Significance of Being on the Frost Radar™

Frost Radar™ Empowers the CEO’s Growth Team

Frost Radar™ Empowers Investors

Frost Radar™ Empowers Customers

Frost Radar™ Empowers the Board of Directors

Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform

Growth Index

Growth Index (GI) is a measure of a company’s growth performance and track record, along with its ability to develop and execute a fully aligned growth strategy and vision; a robust growth pipeline system; and effective market, competitor, and end-user focused sales and marketing strategies.

  • Market Share (previous 3 years)
    This is a comparison of a company’s market share relative to its competitors in a given market space for the previous 3 years.
  • Revenue Growth (previous 3 years)
    This is a look at a company’s revenue growth rate for the previous 3 years in the market/industry/category that forms the context for the given Frost Radar™.
  • Growth Pipeline
    This is an evaluation of the strength and leverage of a company’s growth pipeline system to continuously capture, analyze, and prioritize its universe of growth opportunities.
  • Vision and Strategy
    This is an assessment of how well a company’s growth strategy is aligned with its vision. Are the investments that a company is making in new products and markets consistent with the stated vision?
  • Sales and Marketing
    This is a measure of the effectiveness of a company’s sales and marketing efforts in helping it drive demand and achieve its growth objectives.

Innovation Index

Innovation Index (II) is a measure of a company’s ability to develop products/ services/ solutions (with a clear understanding of disruptive Mega Trends) that are globally applicable, are able to evolve and expand to serve multiple markets and are aligned to customers’ changing needs.

  • INNOVATION SCALABILITY
    This determines whether an organization’s innovations are globally scalable and applicable in both developing and mature markets, and also in adjacent and non-adjacent industry verticals.
  • RESEARCH AND DEVELOPMENT
    This is a measure of the efficacy of a company’s R&D strategy, as determined by the size of its R&D investment and how it feeds the innovation pipeline.
  • PRODUCT PORTFOLIO
    This is a measure of a company’s product portfolio, focusing on the relative contribution of new products to its annual revenue.
  • MEGATRENDS LEVERAGE
    This is an assessment of a company’s proactive leverage of evolving, long-term opportunities and new business models, as the foundation of its innovation pipeline.
  • CUSTOMER ALIGNMENT
    This evaluates the applicability of a company’s products/services/solutions to current and potential customers, as well as how its innovation strategy is influenced by evolving customer needs.

Significance of Being on the Frost Radar™

Companies plotted on the Frost RadarTM are the leaders in the industry for growth, innovation, or both. They are instrumental in advancing the industry into the future.

  • GROWTH POTENTIAL
    Your organization has significant future growth potential, which makes it a Company to Action.
  • BEST PRACTICES
    Your organization is well positioned to shape Growth Pipeline™ best practices in your industry.
  • COMPETITIVE INTENSITY
    Your organization is one of the key drivers of competitive intensity in the growth environment.
  • CUSTOMER VALUE
    Your organization has demonstrated the ability to significantly enhance its customer value proposition.
  • PARTNER POTENTIAL
    Your organization is top of mind for customers, investors, value chain partners, and future talent as a significant value provider.

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Pharmaceuticals research

30 Jul 2026   |   Global   |   Frost Radar

Frost Radar™: Life Sciences Regulatory Information Management Platforms, 2026

The regulatory technology market in life sciences has, over the last five years, quietly transformed from a back-office category dominated by document repositories and submission publishing tools to one of the most consequential software segments serving the pharmaceutical, biotech, and medical devi...

17 Jul 2026   |   Global   |   Technology Research

Innovations and Growth Opportunities in AI-Driven Drug Discovery, Precision Diagnostics, Advanced Biologics, and Next-generation Vaccines

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping drug discovery, diagnostics, and therapeutic delivery across oncology, infectious diseases, rare and autoimmune disorders, metabolic and age...

13 Jul 2026   |   Global   |   Technology Research

RNA Therapies in Rare Diseases

Rare diseases pose a global burden to healthcare despite making up a very small fraction of the global disease landscape. Most treatment options for rare diseases focus on maintaining the disease symptoms, rather than a disease-modifying approach. To address this unmet need, RNA therapies are emergi...

08 Jul 2026   |   Global   |   Technology Research

Precision Obesity Management: AI-Guided Metabolic Modulation

The report explores the transformation of obesity care from generalized BMI-based treatment to AI-enabled precision metabolic management. The study highlights how obesity is increasingly recognized as a heterogeneous, multi-pathway disease influenced by genetic, neurobehavioral, metabolic, and envir...

25 Jun 2026   |   Global   |   Technology Research

Quantum Sensors Transitioning from Lab to Industry: Ultra-Precision Measurement for Healthcare, Defense, and Manufacturing

Quantum sensing is transitioning from laboratory research to industrial deployment, driven by the need for ultra-precise, reliable measurement in high-impact sectors such as healthcare, defense, and advanced manufacturing. This shift reflects a broader move from controlled, research-grade environmen...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

The evolving IT landscape has played a transformative role in the field of life sciences, enabling a reliance on real-world evidence (RWE) solutions. With growing competition and the demand for precision in decision-making, pharmaceutical companies, healthcare providers, and technology organizations have realized the need for real-world data (RWD) to boost research while optimizing clinical trials and improving patient outcomes.

The platforms and enabling technologies help pharma/biotech companies harness regulatory-grade RWE across the product lifecycle, including early-stage research, clinical development, launch planning, value-based contracting, long-term patient monitoring, and patient activation.

The life sciences RWE solutions industry is fragmented, with about 120 vendors operating in this space across areas including data aggregation, integration, interoperability, and predictive analytics to provide pharmaceutical companies with high-quality insights.

Frost & Sullivan screened and analyzed more than 45 RWE solution vendors and short-listed the leading 16 companies based on a detailed analysis of their corporate growth potential and ability to drive visionary innovation in this industry. This Frost Radar™ benchmarks companies primarily in data integration, management, analytics, and insights with a strong play in the data collection segment. Solutions in other segments and enabling technologies had a positive impact on their ratings.

When benchmarking vendors, Frost & Sullivan evaluated their portfolios across key criteria, such as data integration, data quality, advanced analytics, scalability, real-time access, cloud support, collaboration, regulatory expertise, patient-centric approaches, innovation, agility, and cost-effectiveness to ensure that life sciences companies partner with the best vendor for their evolving and customized needs.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar™. The publication presents competitive profiles of each company on the Frost Radar™ considering their strengths and the opportunities that best fit those strengths.

Author: Unmesh Lal
More Information
Deliverable Type Frost Radar
Industries Healthcare
No Index No
Is Prebook No
Keyword 1 Real-world evidence solutions
Keyword 2 RWE vendor benchmarking
Keyword 3 RWE market trends
Podcast No
Predecessor None
WIP Number MHB8-01-00-00-00